Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Sees Large Drop in Short Interest

Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) saw a large drop in short interest in April. As of April 15th, there was short interest totaling 30,580 shares, a drop of 18.8% from the March 31st total of 37,653 shares. Based on an average daily volume of 21,081 shares, the days-to-cover ratio is presently 1.5 days. Currently, 0.6% of the shares of the company are sold short.

Evaxion A/S Price Performance

EVAX stock traded up $0.08 during trading on Friday, hitting $4.49. The company had a trading volume of 30,048 shares, compared to its average volume of 31,768. The company has a fifty day moving average price of $3.82 and a two-hundred day moving average price of $4.70. The company has a current ratio of 5.85, a quick ratio of 5.85 and a debt-to-equity ratio of 0.41. The company has a market cap of $37.45 million, a P/E ratio of -3.40 and a beta of 0.26. Evaxion A/S has a fifty-two week low of $1.42 and a fifty-two week high of $12.15.

Institutional Trading of Evaxion A/S

Several institutional investors have recently bought and sold shares of EVAX. Northwestern Mutual Wealth Management Co. acquired a new position in Evaxion A/S in the fourth quarter worth $38,000. Wesbanco Bank Inc. acquired a new position in Evaxion A/S in the fourth quarter worth $48,000. Finally, SmartHarvest Portfolios LLC acquired a new position in Evaxion A/S in the fourth quarter worth $72,000. Institutional investors and hedge funds own 11.04% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on EVAX shares. Wall Street Zen lowered Evaxion A/S from a “buy” rating to a “hold” rating in a report on Sunday, March 22nd. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price target on shares of Evaxion A/S in a research note on Friday, April 24th. JonesTrading initiated coverage on Evaxion A/S in a research note on Tuesday, March 10th. They issued a “buy” rating and a $10.00 price target on the stock. Maxim Group initiated coverage on Evaxion A/S in a research note on Thursday, February 19th. They issued a “buy” rating and a $10.00 price target on the stock. Finally, Lake Street Capital decreased their price target on Evaxion A/S from $11.00 to $9.00 and set a “buy” rating on the stock in a research note on Monday, March 9th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $11.00.

Evaxion A/S Company Profile

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.